Small Vessel Disease Is Associated with Tissue Inhibitor of Matrix Metalloproteinase-4 After Ischaemic Stroke.
Aged
Aged, 80 and over
Analysis of Variance
Brain Ischemia
/ complications
Cerebral Small Vessel Diseases
/ blood
Cross-Sectional Studies
Female
Humans
Italy
Male
Middle Aged
Stroke
/ complications
Time Factors
Tissue Inhibitor of Metalloproteinase-1
/ blood
Tissue Inhibitor of Metalloproteinases
/ blood
Tissue Plasminogen Activator
/ therapeutic use
Tomography Scanners, X-Ray Computed
Tomography, X-Ray Computed
Tissue Inhibitor of Metalloproteinase-4
Acute stroke
Matrix metalloproteinase
Small vessel disease
Tissue inhibitor of matrix metalloproteinase
Journal
Translational stroke research
ISSN: 1868-601X
Titre abrégé: Transl Stroke Res
Pays: United States
ID NLM: 101517297
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
19
01
2018
accepted:
27
03
2018
revised:
25
03
2018
pubmed:
25
4
2018
medline:
16
4
2019
entrez:
25
4
2018
Statut:
ppublish
Résumé
Small vessel disease (SVD) is frequent in aging and stroke patients. Inflammation and remodeling of extracellular matrix have been suggested as concurrent mechanisms of SVD. We investigated the relationship between imaging features of SVD and circulating metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in patients with ischaemic stroke. In patients treated with intravenous thrombolysis, we took blood samples before intravenous thrombolysis and 90 days after the acute stroke and analysed levels of MMPs and TIMPs. We assessed leukoaraiosis, number of lacunes and brain atrophy on pre-treatment CT scan and graded global SVD burden combining such features. We investigated associations between single features, global SVD and MMPs and TIMPs at baseline and at follow-up, retaining univariate statistically significant associations in multivariate linear regression analysis and adjusting for clinical confounders. A total of 255 patients [mean (±SD) = 68.6 (± 12.7) years, 154 (59%) males] were included, 107 (42%) had no signs of SVD; 47 (19%) had from moderate to severe SVD burden. A total of 107 (42%) patients had no signs of SVD; 47 (19%) had from moderate to severe SVD burden. After adjustment, only TIMP-4 proved associations with SVD features. Brain atrophy was associated with baseline TIMP-4 (β = 0.20;p = 0.019) and leukoaraiosis with 90 days TIMP-4 (β = 0.19; p = 0.013). Global SVD score was not associated with baseline TIMP-4 levels (β = 0.10; p = 0.072), whereas was associated with 90 days TIMP-4 levels (β = 0.21; p = 0.003). Total SVD burden was associated with higher TIMP-4 levels 90 days after stroke, whereas was not during the acute phase. Our results support a biological relationship between SVD grade and TIMP-4.
Identifiants
pubmed: 29687301
doi: 10.1007/s12975-018-0627-x
pii: 10.1007/s12975-018-0627-x
doi:
Substances chimiques
TIMP1 protein, human
0
Tissue Inhibitor of Metalloproteinase-1
0
Tissue Inhibitor of Metalloproteinases
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-51Références
Lancet. 2007 Jan 27;369(9558):275-82
pubmed: 17258667
Neurology. 2015 Feb 24;84(8):825-32
pubmed: 25632086
Neurobiol Aging. 2010 Dec;31(12):2128-35
pubmed: 19128858
Stroke. 2006 Jun;37(6):1391-8
pubmed: 16627790
FEBS Lett. 1997 Jan 20;401(2-3):213-7
pubmed: 9013889
Stroke. 1995 Jan;26(1):52-6
pubmed: 7839397
J Stroke Cerebrovasc Dis. 2017 Jul;26(7):1506-1513
pubmed: 28314624
Neurobiol Aging. 2012 Aug;33(8):1800-6
pubmed: 21601314
Neurology. 2017 Nov 21;89(21):2143-2150
pubmed: 29070665
Lancet Neurol. 2015 May;14(5):485-96
pubmed: 25819484
Int J Stroke. 2016 Jan;11(1):62-7
pubmed: 26763021
Neurology. 2014 Sep 30;83(14):1228-34
pubmed: 25165388
Stroke. 2013 Oct;44(10):2901-3
pubmed: 23908067
J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):192-7
pubmed: 19710048
J Cereb Blood Flow Metab. 1999 Jun;19(6):624-33
pubmed: 10366192
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Stroke. 2015 Jun;46(6):1554-60
pubmed: 25899244
Neuropathol Appl Neurobiol. 2007 Aug;33(4):410-9
pubmed: 17442062
Stroke. 2010 Feb;41(2):267-72
pubmed: 20044528
Acta Neurol Scand. 2017 Jul;136(1):72-77
pubmed: 28233290
Circulation. 2003 Feb 4;107(4):598-603
pubmed: 12566373
Stroke. 2014 Feb;45(2):605-7
pubmed: 24399375
Neurobiol Aging. 2015 Oct;36(10):2806-11
pubmed: 26189091
Stroke. 2001 May;32(5):1162-8
pubmed: 11340226
Lancet Neurol. 2013 May;12(5):483-97
pubmed: 23602162
Cerebrovasc Dis. 2015;40(3-4):157-64
pubmed: 26279056
J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1080-3
pubmed: 2292703
Stroke. 2011 May;42(5):1345-50
pubmed: 21454822
Lancet Neurol. 2010 Jul;9(7):689-701
pubmed: 20610345
Stroke. 2009 Mar;40(3 Suppl):S20-3
pubmed: 19064797
Radiology. 2009 Oct;253(1):174-83
pubmed: 19635835
Stroke. 2003 Mar;34(3):806-12
pubmed: 12624314
Arch Neurol. 1999 Sep;56(9):1104-8
pubmed: 10488811
Hypertension. 2016 Jan;67(1):214-22
pubmed: 26597823
Br J Pharmacol. 2002 Dec;137(8):1330-8
pubmed: 12466243